CLDN6 CAR-T cell therapy (BioNTech)

N/A

Report date: 2026/05/13 15:37:26

Base Information

Drug NameCLDN6 CAR-T cell therapy (BioNTech)
Drug Alias NameAnti-claudin 6 CAR T-cell therapy (BioNTech)CLDN6 RNA-LPXBNT-211
ClassificationVaccines > Application > Therapeutic vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccine
Mechanisms of ActionAnti-CLDN6
TargetsClaudin 6
Therapy Area/IndicationsSolid tumoursTesticular NeoplasmsNeoplasms, Gonadal Tissue +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwedenNetherlands +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiontech Se
China Registration ClassN/A

Develop Information

Active CompaniesBioNTech Cell & Gene Therapies GmbH
Inactive CompaniesBioNTech US IncBiontech Se
Active IndicationsSolid tumours
Inactive IndicationsTesticular NeoplasmsNeoplasms, Gonadal TissueGerminoma

Other Information

ATC CodeN/A
Related LinksN/A